Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

Cécile Tomowiak, Stéphanie Poulain, Charles Herbaux, Aurore Perrot, Béatrice Mahé, Pierre Morel, Thérèse Aurran, Olivier Tournilhac, Stéphane Leprêtre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Delphine Nollet, Damien Roos-Weil, Sylvie Chevret, Véronique Leblond

Blood Adv (2021) 5 (9): 2438–2446.

https://doi.org/10.1182/bloodadvances.2020003895

Published: 2021

Includes: Supplemental data

Journal Articles

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma

Stephan R. Bohl, Laura K. Schmalbrock, Imke Bauhuf, Tatjana Meyer, Anna Dolnik, Martin Szyska, Tamara J. Blätte, Sarah Knödler, Linda Röhner, Denise Miller, Miriam Kull, Christian Langer, Hartmut Döhner, Anthony Letai, Frederik Damm, Dirk Heckl, Lars Bullinger, Jan Krönke

Blood Adv (2021) 5 (9): 2391–2402.

https://doi.org/10.1182/bloodadvances.2020003541

Published: 2021

Includes: Supplemental data

Journal Articles

Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells

Elina Parri, Heikki Kuusanmäki, Daria Bulanova, Satu Mustjoki, Krister Wennerberg

Blood Adv (2021) 5 (7): 1862–1875.

https://doi.org/10.1182/bloodadvances.2020003300

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao, Jacob Glass, Amber C. King, Anthony F. Daniyan, Christopher Famulare, Bernadette M. Cuello, Troy Z. Horvat, Omar Abdel-Wahab, Ross L. Levine, Aaron D. Viny, Eytan M. Stein, Sheng F. Cai, Mikhail Roshal, Martin S. Tallman, Aaron D. Goldberg

Blood Adv (2021) 5 (5): 1552–1564.

https://doi.org/10.1182/bloodadvances.2020003734

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study

Blood Adv (2021) 5 (5): 1442–1451.

https://doi.org/10.1182/bloodadvances.2020003444

Published: 2021

Includes: Supplemental data

Journal Articles

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Blood Adv (2020) 4 (18): 4267–4277.

https://doi.org/10.1182/bloodadvances.2020002846

Published: 2020

Includes: Supplemental data

Journal Articles

Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses

Pierre-Edouard Debureaux, Bruno Cassinat, Juliette Soret-Dulphy, Barbara Mora, Emmanuelle Verger, Nabih Maslah, Aurelie Plessier, Pierre-Emmanuel Rautou, Isabelle Ollivier-Hourman, Victor De Ledinghen, Odile Goria, Christophe Bureau, Claudia Siracusa, Dominique Valla, Stephane Giraudier, Francesco Passamonti, Jean-Jacques Kiladjian

Blood Adv (2020) 4 (15): 3708–3715.

https://doi.org/10.1182/bloodadvances.2020002414

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

Blood Adv (2020) 4 (6): 1038–1050.

https://doi.org/10.1182/bloodadvances.2019001396

Published: 2020

Includes: Supplemental data

Journal Articles

Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma

Blood Adv (2020) 4 (5): 830–844.

https://doi.org/10.1182/bloodadvances.2019000779

Published: 2020

Includes: Supplemental data

Journal Articles

A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients

Yu-Hung Wang, Chien-Chin Lin, Chi-Yuan Yao, Chia-Lang Hsu, Hsin-An Hou, Cheng-Hong Tsai, Wen-Chien Chou, Hwei-Fang Tien

Blood Adv (2020) 4 (4): 644–654.

https://doi.org/10.1182/bloodadvances.2019001185

Published: 2020

Includes: Supplemental data

Journal Articles

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia

Kirk E. Cahill, Yasmin H. Karimi, Theodore G. Karrison, Nitin Jain, Margaret Green, Howard Weiner, Noreen Fulton, Sabah Kadri, Lucy A. Godley, Andrew S. Artz, Hongtao Liu, Michael J. Thirman, Michelle M. Le Beau, Megan E. McNerney, Jeremy Segal, Richard A. Larson, Wendy Stock, Olatoyosi Odenike

Blood Adv (2020) 4 (4): 599–606.

https://doi.org/10.1182/bloodadvances.2019000795

Published: 2020

Includes: Supplemental data

Journal Articles

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Sasanka M. Handunnetti, Neil A. Came, Piers Blombery, David A. Westerman, Meaghan Wall, Constantine S. Tam, Andrew W. Roberts, John F. Seymour

Blood Adv (2020) 4 (1): 165–173.

https://doi.org/10.1182/bloodadvances.2019000864

Published: 2020

Includes: Supplemental data

Journal Articles

Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias

Blood Adv (2019) 3 (23): 3962–3967.

https://doi.org/10.1182/bloodadvances.2019000731

Published: 2019

Includes: Supplemental data

Journal Articles

DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes

Brian Reilly, Tiffany N. Tanaka, Dinh Diep, Huwate Yeerna, Pablo Tamayo, Kun Zhang, Rafael Bejar

Blood Adv (2019) 3 (19): 2845–2858.

https://doi.org/10.1182/bloodadvances.2019000192

Published: 2019

Includes: Supplemental data

Journal Articles

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

Harry P. Erba, Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson, Eunice S. Wang

Blood Adv (2019) 3 (13): 1939–1949.

https://doi.org/10.1182/bloodadvances.2019030916

Published: 2019

Journal Articles

Clinicopathologic and genetic characterization of nonacute NPM1 -mutated myeloid neoplasms

Sanjay S. Patel, Caleb Ho, Ryan N. Ptashkin, Sam Sadigh, Adam Bagg, Julia T. Geyer, Mina L. Xu, Thomas Prebet, Emily F. Mason, Adam C. Seegmiller, Elizabeth A. Morgan, David P. Steensma, Eric S. Winer, Waihay J. Wong, Robert P. Hasserjian, Olga K. Weinberg

Blood Adv (2019) 3 (9): 1540–1545.

https://doi.org/10.1182/bloodadvances.2019000090

Published: 2019

Journal Articles

Germline deletion of ETV6 in familial acute lymphoblastic leukemia

Evadnie Rampersaud, David S. Ziegler, Ilaria Iacobucci, Debbie Payne-Turner, Michelle L. Churchman, Kasmintan A. Schrader, Vijai Joseph, Kenneth Offit, Katherine Tucker, Rosemary Sutton, Meera Warby, Georgia Chenevix-Trench, David G. Huntsman, Maria Tsoli, R. Scott Mead, Chunxu Qu, Vasiliki Leventaki, Gang Wu, Charles G. Mullighan

Blood Adv (2019) 3 (7): 1039–1046.

https://doi.org/10.1182/bloodadvances.2018030635

Published: 2019

Journal Articles

Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition

Céline Moison, Vincent-Philippe Lavallée, Clarisse Thiollier, Bernhard Lehnertz, Isabel Boivin, Nadine Mayotte, Yves Gareau, Mélanie Fréchette, Valérie Blouin-Chagnon, Sophie Corneau, Sylvie Lavallée, Sébastien Lemieux, Anne Marinier, Josée Hébert, Guy Sauvageau

Blood Adv (2019) 3 (4): 552–563.

https://doi.org/10.1182/bloodadvances.2018028480

Published: 2019

Includes: Supplemental data

Journal Articles

Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53

Bridget K. Marcellino, Ronald Hoffman, Joseph Tripodi, Min Lu, Heidi Kosiorek, John Mascarenhas, Raajit K. Rampal, Amylou Dueck, Vesna Najfeld

Blood Adv (2018) 2 (24): 3581–3589.

https://doi.org/10.1182/bloodadvances.2018024018

Published: 2018

Journal Articles

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter

Gregory W. Roloff, Elizabeth A. Griffiths

Blood Adv (2018) 2 (21): 3070–3080.

https://doi.org/10.1182/bloodadvances.2018020206

Published: 2018

NARROW

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma

Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma

A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias

DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

Clinicopathologic and genetic characterization of nonacute NPM1 -mutated myeloid neoplasms

Germline deletion of ETV6 in familial acute lymphoblastic leukemia

Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition

Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only